Integrins as therapeutic targets for angiogenesis and metastasis

Mohit Trikha. Centocor, 200 Great Valley Parkway, Malvern, PA, USA. In vivo tumors interact with a variety of host cells such as endothelial cells and platelets, and these interactions are mediated by integrins GPIIb/IIIa and ανβ3. We used chimeric (c) 7E3 Fab (abciximab, ReoPro™) and murine (m) 7E3 F(ab')2 to elucidate the role of host and tumor-derived integrins in angiogenesis, tumor growth and metastasis. c7E3 Fab is used in patients undergoing precutnaneous coronary interventions. These antibodies are potent inhibitors of GPIIb/IIIa and crvβ3. c7E3 Fab inhibited av \$3-mediated cell adhesion, migration, invasion and bFGF stimulated proliferation of endothelial cells. In an in vitro angiogenesis assay, c7E3 Fab inhibited bFGF- and platelet-stimulated capillary formation of endothelial cells (IC₅₀=10-15 µg/ml), demonstrating that endothelial $\alpha v\beta 3$ is important for sprouting, and platelet-stimulated sprouting is mediated by GPIIb/IHa. In a hung metastasis assay, a single treatment of human melanoma cells with c7E3 Fab (2.5 µg/ml) inhibited hing colonization of the tumor cells in SCID mice. In vivo, m7E3 F(ab')2 partially inhibited growth of human melanoma tumors in nude mice compared to control treated animals. Since c7E3 Fab and m7E3 F(ab')2 do not crossreact with murine integrins, this inhibition of metastasis and tumor growth was attributable to direct blockade of human tumor av \beta3 integrins. m7E3 F(ab')2 completely blocked tumor formation and growth of human melanoma tumors in nude rats. In this xenograft model, m7E3 F(ab')2 binds to both human tumor and host platelet GPIIb/IIIa and endothelial ανβ3 integrins, thus participating as an anti-angiogenic, antiplatelet and anti-tumor agent. Collectively, these results indicate that combined blockade of GPIIb/IIIa and crvβ3 affords anti-angiogenic and anti-metastatic benefit.